Aim immunotech announces phase 2 study of ampligen® for the treatment of pancreatic cancer is open and recruiting patients

Ongoing efforts to open additional clinical sites for recruitment at premier cancer centers across the u.s. and europe are in progress to facilitate patient enrollment and dosing ongoing efforts to open additional clinical sites for recruitment at premier cancer centers across the u.s. and europe are in progress to facilitate patient enrollment and dosing
AIM Ratings Summary
AIM Quant Ranking